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Infections take their greatest toll in early life necessitating robust approaches to protect the 
very young. Here, we review the rationale, current state, and future research directions for 
one such approach: neonatal immunization. Challenges to neonatal immunization include 
natural concern about safety as well as a distinct neonatal immune system that is generally 
polarized against Th1 responses to many stimuli such that some vaccines that are effective 
in adults are not in newborns. Nevertheless, neonatal immunization could result in high-pop-
ulation penetration as birth is a reliable point of healthcare contact, and offers an opportunity 
for early protection of the young, including preterm newborns who are deficient in maternal 
antibodies. Despite distinct immunity and reduced responses to some vaccines, several vac-
cines have proven safe and effective at birth. While some vaccines such as polysaccharide 
vaccines have little effectiveness at birth, hepatitis B vaccine can prime at birth and requires 
multiple doses to achieve protection, whereas the live-attenuated Bacille Calmette–Guérin 
(BCG), may offer single shot protection, potentially in part via heterologous (“non-specific”) 
beneficial effects. Additional vaccines have been studied at birth including those directed 
against pertussis, pneumococcus, Haemophilus influenza type B and rotavirus providing 
important lessons. Current areas of research in neonatal vaccinology include characteriza-
tion of early life immune ontogeny, heterogeneity in and heterologous effects of BCG vaccine 
formulations, applying systems biology and systems serology, in vitro platforms that model 
age-specific human immunity and discovery and development of novel age-specific adju-
vantation systems. These approaches may inform, de-risk, and accelerate development of 
novel vaccines for use in early life. Key stakeholders, including the general public, should be 
engaged in assessing the opportunities and challenges inherent to neonatal immunization.
Keywords: neonatal, vaccine, protection, trained immunity, novel adjuvants
iNTRODUCTiON
Despite the success of the Millenium Development Goal era from 2000 to 2015, during which the 
under five mortality rate was reduced by 53%, ~ 2 million infants under 6 months die annually due 
to infections (1). Of the 5.9 million children under 5 years of age who died in 2015, 45% were in the 
first month of life (2). Many of these deaths are attributed to vaccine preventable illnesses, occurring 
before protection is afforded by routine immunization given as part of the expanded program of 
immunization (EPI). Although this commences at 6–8 weeks of age, the first dose does not provide 
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immediate protection and multiple doses are required, leading to 
vulnerability in the first 6 months of life. In an effort to reduce the 
under 5-year old mortality rate further, to ≤25/1,000 live births 
by the end of 2030, a number of strategies are being explored 
and implemented as part of the sustainable development goal-3. 
These include maternal immunization, which, although it shows 
great promise for a number of pathogens, including pertussis 
and influenza, is limited by safety and ethical concerns, and is 
of limited value for the ~2.6 million infants born preterm, prior 
to maternal antibody (Ab) transfer (3). The reality, that we rely 
on immunization occurring early in life, coupled with recent 
advances in our understanding of neonatal immune responses 
(4–6), has led to renewed interest in neonatal immunization as a 
promising and effective strategy, to reduce morbidity and mortal-
ity in young infants. Thus, the topic of early life immunity, and in 
particular neonatal immunization, is one of tremendous public 
health relevance.
Great strides in vaccine development over the last century 
have resulted in a number of effective vaccines being given in 
early life, but only Bacille Calmette–Guérin (BCG), hepatitis 
B (HBV), and polio vaccine [oral polio vaccine (OPV); or 
inactivated polio vaccine (IPV)] have been routinely recom-
mended at birth. For some pathogens, including pertussis and 
tuberculosis (TB), better vaccines are needed, while for others 
such as human immunodeficiency virus (HIV) and respiratory 
syncytial virus (RSV), efficacious vaccines have yet to be devel-
oped and licensed for any age group. Among the approaches 
to improving protection against infection in early life, neonatal 
immunization is ripe for further research and development. 
Herein, we review the rationale for neonatal immunization 
and highlight essential research areas, including the study of 
immune ontogeny and the development of vaccines optimized 
for early life administration.
Rationale for Use of vaccines in the 
Neonatal Period
The neonatal period is defined as the first 28 days of life. For 
the purpose of this review, we define neonatal vaccines as those 
given “at birth” or within the first 28 days of life. Of note, EPI 
vaccines are licensed to be given within the first few weeks of 
life, and in reality, the “birth dose” is given across a range of 
time in the first month of life, a variability that to our knowledge 
has not been systematically studied with respect to relative 
vaccine efficacy. In contrast, we define infant vaccines as those 
given after the first 28 days of life. In countries following the 
EPI schedule, after the neonatal doses of BCG, HBV, and polio 
vaccines, the next EPI schedule dose is typically given between 
6 and 8 weeks of life. As with any vaccine approach, develop-
ment of neonatal vaccines must take into account potential 
limitations, including: (a) need to establish safety, (b) lack of 
effectiveness of some vaccines in early life, (c) challenges of a 
translational path that typically starts with formulations opti-
mized for adults, rather than generating formulations that are 
optimal for the young, and (d) potential blunting of neonatal 
Ab responses after maternal immunization. Nevertheless, the 
rationale for neonatal immunization is robust and includes: 
(a) the heavy burden of early life infection; (b) that birth is a 
practical point of healthcare contact, and pairing immuniza-
tion with birth may lead to health benefits for both mothers 
and newborns; (c) immunization at birth may provide earlier 
protection than existing immunization schedules; (d) the likely 
benefit of protection to babies born preterm for whom maternal 
Ab transfer is limited, with an increased risk of serious infec-
tions throughout childhood (7); and (e) emerging evidence that 
the heterologous benefit of the live-attenuated BCG vaccine and 
other live vaccines may be greatest in early life (8).
LeSSONS FROM iMMUNe ONTOGeNY
Neonatal immunization occurs in a backdrop of distinct early 
life immunity. Recent reviews have highlighted that both cellular 
and soluble aspects of the immune system are distinct at birth 
(9, 10). Neonatal immunity must not only defend the newborn 
against a potential onslaught of potential pathogens, but also 
mediate the acquisition of a colonizing microbiome over the 
first hours and days of life. In this context, neonatal immune 
responses are apparently designed to avoid excessive inflamma-
tion with a generally reduced production of pro-inflammatory 
and Th1-polarizing cytokines to microbial components/pattern 
recognition receptors (PRR) agonists. Age-specific composition 
of soluble and cellular factors shape neonatal immunity. The 
distinct composition of human newborn cord blood plasma 
includes soluble mediators such as maternal Abs, high levels 
of immunosuppressive adenosine, and low levels of comple-
ment, important for triggering adaptive immune responses 
(11). Accordingly, modeling age-specific immunity in  vitro 
should take into account distinct composition of age-specific 
autologous plasma, rather than, for example, fetal bovine 
serum (9). Distinct cellular immunity in the newborn includes 
reduced Th1 but robust anti-inflammatory IL-10 responses of 
antigen-presenting cells to stimulation by PRR agonists, high 
frequency of naïve- and regulatory-T cells and CD71+ erythroid 
precursors that may limit, for example, responses to pertussis 
immunization (10, 12, 13). Nevertheless, neonatal immunity 
is capable of mounting antigen-specific effector responses, as 
demonstrated by BCG-specific IFNγ production following vac-
cination at birth (14). Overall, detailed study and modeling of 
age-specific human immunity may help inform development of 
vaccine formulations, with or without adjuvants as needed, that 
may trigger a protective immune response in early life.
PROOF OF CONCePT: ROUTiNe 
NeONATAL vACCiNeS
Bacille Calmette–Guérin
Bacille Calmette–Guérin is a live-attenuated strain of 
Mycobacterium bovis. Given in areas with high-endemic TB 
to prevent disseminated TB in infancy, BCG is the most com-
monly given vaccine with ~4 billion doses administered to date. 
Although it has been administered for nearly 100 years, several 
key issues regarding BCG have emerged, including: (a) lack of 
a clear correlate of protection (CoP); (b) marked heterogeneity 
TABLe 1 | Immunizations given at different ages.
vaccines 
licensed
vaccines tested Future vaccine 
targets
Pregnancy •	 aPertussis
•	 Tetanus
•	 Influenza
•	 (RSV)
•	 GBS
•	 Group B 
Streptococcus
•	 HIV
•	 Malaria
Birth •	 OPV
•	 HepB
•	 BCG
•	 DTaP
•	 Hib
•	 PCV
•	 Malaria (e.g.,  
RTS,S/ASO1/2)
•	 Recombinant  
BCG vaccines  
(e.g., VPM1002)
•	 HIV (phase I/IIa)
•	 Rotavirus
•	 RSV
•	 Salmonella
•	 ETEC
•	 ncHI
•	 Malaria
Infant doses
Age 2–4 months
•	 DTaP and 
DTwP
•	 IPV
•	 Hib
•	 HepB
•	 PCV
•	 MenB
•	 MenC
•	 Rotavirus
•	 Malaria (e.g., RTS, 
S/ASO1/2, and 
Spf66)
•	 Recombinant BCG 
vaccines  
(e.g., VPM1002)
•	 Novel TB candidates 
(e.g., MVA85A)
•	 HIV (phase I/IIa)
•	 RSV
•	 Men ACWY
•	 Salmonella
•	 ETEC
•	 ncHI
•	 Malaria
Infant doses
Age 12–13 months
•	 Hib
•	 PCV
•	 MMR
•	 MenB
•	 MenC
•	 Varicella
•	 LAIV
RSV (respiratory syncytial virus), Hib (haemophilus influenzae B), BCG (Bacille Calmette–
Guerin), OPV (oral polio vaccine), IPV (inactivated polio vaccine), HepB (hepatitis B), DTaP 
(diphtheria, tetanus, acellular pertussis), DTwP (diphtheria, tetanus, whole cell pertussis), 
PCV (pneumococcal conjugate vaccine), HIV (human immunodeficiency virus), ETEC 
(enterotoxic Escherichia coli), ncHI (non-encapsulated Haemophilus influenzae), Men B,C, 
ACWY (meningococcal B,C, ACWY), MMR (measles, mumps, rubella), TB (tuberculosis), 
LAIV (live-attenuated influenza virus). ( ) indicates Trial in progress.
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between licensed BCG formulations (15); and (c) growing 
evidence that BCG has heterologous (“non-specific”) beneficial 
effects, particularly when administered in newborns (16). It is 
hypothesized that these non-specific benefits may protect against 
unrelated infections, supporting the use in neonates, beyond 
any protection against TB infection or disease. Furthermore, 
association studies suggest that early immunization with BCG-
containing regimens may protect against leukemia, allergy, and 
childhood diabetes among others, possibly via heterologous 
trained immunity (17–19).
A CoP is an immune measure that corresponds to vaccine-
induced protection from disease (20). Despite substantial 
efforts to characterize classic adaptive immunity, including 
multiple studies of polyfunctional CD4 T  cells, a clear CoP 
for BCG has yet to be established (21). Indeed, increasing 
evidence that BCG induces trained immunity—i.e., enhanced 
subsequent innate responses to a range of stimuli (8)—raises 
the possibility that these innate immune enhancing effects 
may not only underlie heterologous (non-specific) benefits of 
BCG vaccine, but may also contribute to, or conceivably be, 
the major factor in the so called “specific” effect of BCG, i.e., 
protection against early life TB.
A critical issue with respect to BCG immunization is marked 
variability between vaccine formulations produced in different 
production facilities, with the result that “BCG” is not a single 
entity. After its original manufacture in the Pasteur Institute 
(Paris, France) in 1921, BCG was shipped to 20 different interna-
tional sites where the vaccine was repeatedly subcultured under 
different conditions. This has resulted in diverse licensed BCG 
formulations that are distinct both by content of live mycobacte-
ria as well as genetic composition. These strains have been shown 
to have differing immune responses and furthermore, the clini-
cal relevance of this has been illustrated in comparative studies, 
which suggest, for example, that BCG-Denmark and BCG-Japan 
may have greater benefit in reducing TB disease than BCG-Russia 
(15, 22).
Much remains to be learned regarding mechanisms underly-
ing BCG-induced protection. As a complex vaccine comprised 
of live-attenuated mycobacterium, BCG engages the innate 
immune system via PRRs. Analogy to M. tuberculosis as well as 
direct human in vitro studies suggests that BCG may activate via 
multiple toll-like receptors (TLRs) including TLRs-2, -4, -7, -8, 
and -9 as well as C-type lectin receptors and NLRs (23). Studies 
of BCG-immunized adults demonstrate a re-programing of 
monocyte precursors such that the higher expression of PRRs 
and greater reactivity to stimuli such as TLR agonists. This innate 
immune enhancing effect of BCG is reminiscent of the effect of 
administration of TLR agonists to neonatal mice that enhanced 
innate immune responses, including cytokine induction and 
phagocyte recruitment, and improved bacterial clearance and 
survival in a model of neonatal sepsis (24). Such innate immune 
enhancing effects of prior stimulation have been termed “trained 
immunity” reflecting an adaptive arm of innate immunity that is 
noted in plants, insects, and mammals (25). That BCG heterolo-
gous (non-specific) benefits are greater in early life (26) suggests 
ontogeny of underlying immune mechanisms, potentially includ-
ing trained immunity (27).
Hepatitis B vaccine
Hepatitis B vaccine is an alum-adjuvanted vaccine containing 
hepatitis B surface antigen (HBsAg). The alum-adjuvanted HBV 
is given within the EPI (Table 1) and also in Australia, Europe, 
and United States, where a birth dose is recommended (28). With 
respect to innate immune activation, while the Alum adjuvant 
present in HBV may engage the inflammasome, HBsAg also 
interacts with CD14 to activate dendritic cells (29). Importantly, 
there is a measurable CoP for HBV, namely the titer of anti-HBsAg 
Abs. Although this CoP has been defined, as with many vaccines, 
it is not fully understood how HBV vaccine induces protective 
immunity, as a newborn dose is protective, despite only ~30–50% 
of newborns responding with “protective” titers after a single dose. 
This observation suggests that additional mechanisms, including 
cell-mediated immunity (CMI), may contribute to protection 
(30). Ab and T cell responses to HBV given to infants are distinct 
from those of adults, in that infants produced markedly higher 
serum anti-hepatitis B surface (HBs) Ab titers in one study, and 
low-Ab levels were associated with lower HBs Ag-specific IFNγ 
responses and a more Th2-polarized memory response to HBsAg 
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at 1 year (30). Genetic factors, low-birth weight and low-Apgar 
scores were risk factors for poor HBV response in a study of twins 
in China (31). Haplotype analysis of Gambian infants suggested 
that CDC42, IL19, and IL1R1 genes associated with peak anti-
HBsAg Ab level (32). Much remains to be learned regarding how 
HBV protects in early life.
Polio
A birth dose of OPV has been recommended by the World Health 
Organization since 1984. It is hypothesized that a birth dose of 
OPV may induce mucosal protection prior to colonization or 
infection with enteric organisms which may interfere with the 
immune response to doses given later in life. Data on seroconver-
sion following this individual dose of trivalent OPV (tOPV) vary 
greatly, from 10 to 15% in India to 76% in South Africa, however, 
the positive impact on levels of neutralizing Abs and seroconver-
sion rates on completion of the routine immunization schedule are 
undisputed (33). A systematic review of 5,257 infants given tOPV 
at birth, found that the percentage of newborns who seroconverted 
at 8 weeks ranged between 6 and 42% for poliovirus type 1, 2 and 
63% for type 2, and 1 and 35% for type 3 (34). In addition, there 
were four studies of IPV in newborns with a seroconversion rate 
of 8–100% for serotype 1, 15–100% for serotype 2, and 15–94% 
for serotype 3, measured at 4–6 weeks of life. No serious adverse 
events related to OPV or IPV doses at birth were reported in 
these studies, including no cases of acute flaccid paralysis. Some 
groups have advocated a shift to using IPV because (a) tOPV has 
been associated with rare cases of vaccine-associated paralytic 
poliomyelitis (~2–4 cases/million), (b) concerns about the use of 
live vaccines in immunocompromised individuals, including those 
with HIV infection, and (c) potential risk of strain reversion. Of 
note, however, some studies have suggested that similarly to BCG 
vaccine, a birth dose of live OPV may induce heterologous (“non-
specific”) beneficial effects (35). Further research is warranted 
prior to replacing OPV with IPV (36).
CLiNiCAL STUDieS OF OTHeR vACCiNeS 
AT BiRTH
Pertussis
Initial studies of the role of a birth dose of whole cell pertussis 
vaccine demonstrated low-Ab titers at 4 months, although there 
were no randomized studies at that time comparing a birth 
dose with a dose at 6–8  weeks of age (37). Further studies of 
neonatal whole cell pertussis immunization were deterred by 
the suggestion in 1965 that immunization with the whole cell 
pertussis vaccine combined with diphtheria and tetanus toxoids 
(DTwP) within 24 h of birth may introduce “immune paralysis” 
(38). Twenty years later, comparison studies of a birth dose of 
DTP with routine immunization at 2  months demonstrated 
significantly lower titers to pertussis toxin (PT) at 9  months 
of age, and an inverse correlation between cord Ab titers and 
infant responses (39). Safety concerns about the whole cell vac-
cine led to a switch to acellular pertussis vaccines (aP, or DTaP) 
in the 1990s. Initial neonatal studies of aP vaccines, both with 
and without diphtheria and tetanus antigens, were promising 
(40, 41), but a conflicting later study showed poorer responses 
(42). Reports of bystander interference resulting in lower 
Haemophilus influenza type B (Hib) vaccine and HBV responses 
were concerning (41). A pilot study of the GSK monovalent aP 
vaccine at birth and 4 weeks demonstrated significantly higher 
IgG Ab against pertussis antigens at 2 months of age, without 
reducing subsequent pertussis Ab responses. A larger study 
of doses at birth and 6 weeks, including influence of maternal 
immunization, on Ab responses up to 5  years of age is ongo-
ing (43, 44). Follow-up of children from the initial pilot study 
to 4  years of age demonstrated higher cytokine responses to 
pertussis antigen stimulation in those who received a birth dose 
compared with controls at 2 years of age (44). These observations 
were similar to those in a long-term follow-up study of children 
vaccinated at birth which showed increasing CMI, as measured 
by lymphoproliferative capacity, compared with controls (45). 
As the role of maternal immunization with pertussis becomes 
more established, it is crucial to include the effect of maternal 
interference in studies, as even pre-pregnancy immunization 
may influence later-born infant responses (46). Englund et  al. 
demonstrated a lack of maternal Ab interference on infant 
immunizations given at 2 months—that is, the PT Ab response 
to DTaP, unlike DTwP, was not affected by pre-existing Ab to PT 
(47). Whether this observation also holds true for birth doses 
requires future study. Given current concerns of waning immu-
nity to aP (48), novel pertussis vaccine formulations, potentially 
including developing pertussis vaccines that are safe and effective 
in newborns, are needed to induce robust and durable immunity 
against this pathogen.
Haemophilus influenza Type B
The role of a birth dose of Hib vaccine was explored by a number 
of groups following the initial success of its introduction into the 
EPI. Three different conjugate vaccines tested {HIB polysaccha-
ride conjugated to tetanus toxoid, Hib polysaccharide conjugated 
to a genetically modified diphtheria toxin (HbOC), and Hib 
polysaccharide conjugated to a Neisseria meningitidis outer mem-
brane protein [HbOMP; subsequently noted to be a TLR2 agonist 
(49)]} all resulted in significantly higher PRP Ab levels at 2 or 
4 months compared with controls, suggesting neonatal priming 
was possible (50, 51). However, these higher Ab levels did not 
persist for HbOC and declined more rapidly than controls for 
HbOMP, leading to concerns about waning protection. Further 
studies have not been undertaken, as epidemiological studies 
have demonstrated a protective effect of herd immunity on early 
life burden of invasive Hib disease, presumed due to reduction of 
asymptomatic nasopharyngeal carriage of Hib among vaccines 
(52, 53). Conjugate vaccines, through a T cell-dependent immune 
response, result in very high-protective Ab responses in infants 
of all ages, which results in reduction of carriage. Furthermore, 
the licensed 10 valent pneumococcal conjugate vaccine (PCV10; 
PHid-CV), uses a Haemophilus outer membrane protein (protein 
D) as its carrier protein, and immunization with this reduces 
the incidence of all invasive Haemophilus spp. disease, includ-
ing non-typable or non-encapsulated Haemophilus influenzae 
(ncHI). This may be of particular importance as invasive disease 
due to ncHI is commonest in the first month of life (54, 55), so the 
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potential role of the PHid-CV pneumococcal vaccine or a specific 
ncHI vaccine in neonates should be studied.
Pneumococcal Conjugate vaccine
To date, only two published trials have assessed effects of a neona-
tal dose of the seven valent PCV7 (56, 57). In Kenya, 300 neonates 
were randomized to receive PCV7 at birth, 10 and 14 weeks or at 
6, 10, and 14 weeks (EPI schedule). The safety of giving vaccine at 
birth was an important endpoint in the study and the researchers 
saw no significant difference in safety events between the two 
groups. Serotype-specific IgG binding was measured following 
the completion of the primary infant schedule at 18 weeks of age. 
The proportion of infants who had an Ab concentration above 
the accepted protective threshold of >0.35 μg/mL was similar 
between the two groups. When a higher threshold (>1.0 µg/mL) 
was used, proportions above 1 for serotypes 4, 18 C, 19 F were 
lower in the neonatal group. Geometric mean concentrations 
of IgG for four serotypes (4, 9V, 18 C, 19 F) were lower in the 
neonatal group compared with the EPI group at 18 weeks of age. 
In contrast, the mean avidity indices were significantly higher 
in the neonatal group for three of the four serotypes tested (4, 
6B, 19 F) (57). In both groups, maternal IgG measured in cord 
blood inversely correlated with the GMC at 18 weeks of age with 
high-serotype specific cord blood levels associated with lower 
responses to vaccine. At 9  months of age, 5  months following 
the third PCV dose, there was no difference in the percentage of 
infants with an Ab concentration above either the 0.35 or 1.0 µg/
mL thresholds. The GMC of serotype 4 specific IgG remained 
lower and serotype 19  F avidity index remained higher in the 
neonatal group. Responses to a booster dose of PCV given at 
9 months of age and measured 2 weeks later were comparable 
between the two groups suggesting that there is no tolerance 
induced by the neonatal dose. Carriage was measured at 18 and 
36 weeks in this study with no significant differences detected 
between the groups.
In a trial undertaken in Papua New Guinea (PNG), 318 infants 
were randomized to receive either PCV7 at birth, 1 and 2 months, 
PCV7 at 1–3 months, or no PCV7 (56). Local reactogenicity rates 
were generally low although higher rates were seen in the infant 
than the neonatal group. There were no differences in the illness 
episodes or serious adverse events. At 2 months of age, serotype-
specific GMCs were significantly higher in the neonatal group 
than in the infant group for four of the seven serotypes in PCV7 
(4, 9V, 18 C, 19 F). At this point, the neonatal group had received 
two doses of PCV compared with one dose in the infant group. By 
4 months of age, following three doses of the vaccine, GMCs were 
significantly higher for all serotypes in the infant group than in the 
neonatal group although 2 months had elapsed since the neonatal 
groups third dose, a gap that was only 1 month for the infant group. 
Comparable responses were seen following a pneumococcal poly-
saccharide vaccine administered at 9 months of age and responses 
in both PCV7 primed groups were significantly greater than 
responses in those who were not primed. Nasopharyngeal swabs 
were collected at ages 1–4 weeks and 3, 9, 18 months, and middle ear 
discharge if present. The prevalence of pneumococcal carriage was 
22% at 1 week of age, rising to 80% by age 3 months and remained 
>70% thereafter (58). There were no significant differences in PCV7 
serotype carriage between PCV recipients and controls at any age 
(22 vs. 31% at 9 months, p = 0.2). At age 9 months, the prevalence 
of non-PCV7 serotype carriage was 17% higher in PCV7 recipients 
(48%) than in controls (25%, p = 0.02). The authors attributed the 
limited impact of neonatal or accelerated infant PCV7 schedules on 
vaccine serotype carriage to the early onset of dense carriage of a 
broad range of pneumococcal serotypes.
A prior report from the same PNG study examined whether 
a neonatal PCV7 dose might induce immune tolerance (59). In a 
comprehensive immuno-phenotypic analysis at 9 months of age, 
no differences in the quantity or quality of vaccine-specific T cell 
memory responses (including responses to CRM197, tetanus 
toxoid, and HBsAg) were found between the neonatal and infant 
vaccination groups. Hospitalization rates in the first month 
of life did not differ between children vaccinated with PCV at 
birth or not. Reviewing the data outlined in these two studies 
demonstrates that neonatal immunization with PCV7 is safe and 
not associated with immunologic tolerance (56, 58).
CURReNT ReSeARCH ON eARLY LiFe 
iMMUNiZATiON
enhancing Current vaccines
One approach to developing enhanced neonatal vaccines 
focuses on improving existing vaccines such as the live “self-
adjuvanted” BCG vaccine. For example, the BCG-derivative 
VPM1002 expresses listeriolysin from Listeria monocytogenes 
designed to enhance MHC-I responses (60). In a phase II open 
label study comparison with conventional BCG-SSI in South 
African newborns (n =  48), VPM1002 demonstrated safety 
and immunogenicity with an increased proportion of CD8+ 
IL-17+ cells at 6 months post-vaccine. The authors speculate 
that although the significance of such cells is unknown, it is 
possible that they could contribute to more robust protection 
against TB and that larger studies are needed to assess this 
possibility.
Development of Adjuvants for early Life 
immunization
Another approach to enhancing vaccine responses in infants 
with “age-appropriate” immunity is the addition of adjuvantation 
systems to enhance vaccine immunogenicity and efficacy. PRR 
agonists such as mono-phosphoryl lipid A that activates TLR4, 
have been employed as vaccine adjuvants but the translational 
path for this approach must take into account that responses to 
PRR stimulation vary markedly with the age of a given individual 
(6). In developing adjuvant systems optimized to early life, there 
may be lessons to learn from live-attenuated vaccines currently in 
use. Examples from human in vitro studies using the BCG vaccine 
demonstrate this, including TLR2-mediated activation of neona-
tal NK cells to produce IFNγ; TLR9-mediated activation of pDCs 
for IFNγ; TLR2- and IFN-mediated activation of conventional 
DCs IL-12 p70 production and subsequent CD4+ T-cell Th1 
polarization (61). Along these lines, TLR7/8 adjuvant-containing 
nanoparticles mimic effects of BCG on human neonatal mono-
cyte-derived DCs in vitro and induce anti-mycobacterial T cells 
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in humanized TLR8 mice in  vivo (62). Addition of a TLR7/8 
agonist adjuvant to PCV dramatically accelerated and enhanced 
responses to a birth dose, inducing pneumococcal-specific Ab 
titers far exceeding the CoP after a single dose (63). As with any 
vaccine development, safety will be front and center, and in this 
context, it is worth noting that the most commonly given neona-
tal vaccine, BCG, activates multiple PRRs including TLRs and is 
safely given to newborns across the globe. Although this does not 
necessarily imply that any TLR-stimulating approach would be 
safe, it does provide an important proof of concept that in certain 
settings and contexts, PRR activation including TLR-stimulation 
can be safe and effective approach to vaccine adjuvantation in 
human newborns.
Mucosal vaccine Development
In designing new vaccines to be given in the neonatal period, 
consideration must be given to ideal characteristics (64). 
Mucosal vaccines, with their potential for needle-free delivery, 
are very attractive. A number of the pathogens causing severe 
disease in early infancy are mucosally transmitted [rotavi-
rus, RSV, polio, non-typable Salmonella spp., enterotoxic 
Escherichia coli (ETEC)] and the positive experience with OPV 
provides proof of concept of mucosal vaccines in this age group. 
Mucosal vaccines could be administered by a number of routes 
(oral, nasal, conjunctival, rectal, and vaginal) with nasal and 
oral being the most practical and studied to date. Adjuvanted 
mucosally administered vaccines stimulate multiple types of 
immune responses, including secretory IgA Abs which prevent 
adhesion and invasion of pathogens, serum IgG neutralizing 
Abs, and a wide array of cell-mediated T cell responses (65). 
Of note, determining the correlate of immune protection for 
each vaccine is a challenge. The focus has historically been 
on neutralizing IgG antibodies, but increasingly, the role of 
antigen-specific IgA in serum and stool has been explored (66) 
with need for further standardization of these assays. A number 
of factors may influence the efficacy and immunogenicity of 
oral vaccines, particularly in early life, including the presence 
of pre-existing Abs, malnutrition, enteropathy, micronutrient 
deficiencies, and breast feeding, factors being studied in the 
context of OPV and rotavirus vaccines (67). Breast milk con-
tains an array of protective molecules including specific Abs, 
oligosaccharides, glycoproteins, and receptor analogs, likely 
to prevent both pathogenic- and vaccine-strains of micro-
organisms binding to the intestinal wall. A study of Rotarix in 
infants comparing withholding or not withholding breastfeed-
ing around the time of vaccine administration did not dem-
onstrate an increase in anti-rotavirus IgA seroconversion (68). 
To the extent that these factors may limit responses to mucosal 
vaccines, neonates, who are unlikely to yet have malnutrition, 
enteropathy, and co-infections, may be more responsive to oral 
vaccines.
A number of oral vaccines with varying immunogenic and 
protective efficacies have been licensed including those directed 
against typhoid, rotavirus, polio, and cholera. Other targets 
include non-typable Salmonella, ETEC, Shigella, and adenovirus 
(64). Few to date have been studied in newborns, although diar-
rheal illness accounts for many of the deaths in infants <6 months 
of age, with rotavirus identified as a leading cause of dehydrating 
gastroenteritis, associated with ~28% of diarrheal deaths (69). 
Two live-attenuated oral rotavirus vaccines, the pentavalent 
human-bovine rotavirus vaccine, RotaTeq, given as three oral 
doses a month apart; and monovalent human rotavirus vaccine 
Rotarix, given as two doses a month apart; were licensed in 2006. 
Protection against severe disease in high- and middle income 
countries is excellent for both (80–95% efficacy). However, 
unfortunately, these rotavirus vaccines have been less efficacious 
in low-income regions where the need is far greater such as sub-
Saharan Africa (46% efficacy) and in Southern Asia (50%) (70). 
Although indirect benefits of rotavirus vaccine, such as those 
realized via herd immunity and protection, have been described 
in high- and middle income countries, this has not been firmly 
established in low-income countries to date (71). Factors includ-
ing breastmilk Abs, concurrent infections, or environmental 
enteropathy may interfere with the efficacy of the oral rotavirus 
vaccine (67). Administration of a birth dose could potentially 
ameliorate these concerns, as well as provide protection in the 
vulnerable gap when the most severe disease occurs, between 
birth and the protective response induced by a first dose given at 
6 weeks of age (72). Furthermore, the risk of intussusception as a 
complication of rotavirus vaccine appears to follow an age-related 
pattern, supporting a neonatal schedule over an infant schedule 
for this vaccine (73). A phase IIa study of a monovalent human 
rotavirus vaccine RV3-BB, including a neonatal dose, demon-
strated a rotavirus IgA response rate of 11% with stool excretion 
of 13% after one dose (74). Overall immunogenicity following the 
non-neonatal schedule at 8, 15, and 24 weeks was 50% after two 
doses and 74% after 3. A nested study within the trial examined 
the relationship between rotavirus-specific IgA in cord blood, 
colostrum and breast milk and infant serum IgA response and 
stool excretion and found no evidence of an association (75). 
Although these initial immunogenicity results are disappointing, 
with low uptake following the neonatal dose, neither RotaTeq 
nor Rotarix have been tested in the neonatal period such that 
further studies of rotavirus vaccines in the neonatal period are 
warranted.
A nasally delivered live-attenuated influenza vaccine 
(LAIV) has been effective in infants in protection from flu, 
but has not to date been tested in neonates. Infants between 6 
and 12 months experienced relatively high rates of hospitaliza-
tion in an RCT comparing inactivated vaccine and LAIV and 
consequently, LAIV has only been recommended in infants 
greater than 12  months of age (76). There is currently no 
available influenza vaccine for infants younger than 6 months, 
however, maternal immunization provides passive protection 
(77) and in a murine model, there was no evidence of maternal 
interference (78).
As a leading cause of morbidity and mortality in the neonatal 
and early infancy period, RSV is an ideal target for a mucosal 
vaccine (79). The RSV fusion (F) surface glycoprotein has 
been considered as one of the two major protective antigens 
for eliciting neutralizing Abs; a humanized monoclonal Ab 
specific to the F protein (Palivizumab), administered monthly 
to vulnerable infants during the RSV season, is efficacious in 
preventing severe disease, but not infection (80). Low levels of 
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nasal RSV-specific IgA are a risk factor for RSV disease in adults 
(81), but as yet, although animal models have demonstrated 
neutralizing Abs in response to RSV vaccine candidates, specific 
IgA production has not been shown (82, 83). Animal models of 
live-attenuated vaccines provide grounds for optimism (84) and 
phase I studies of virus-vectored vaccines in adults have been 
promising (85), but virus-vectored RSV vaccines have not yet 
been trialed in infants. Development of vaccines based on the 
RSV pre-fusion protein, an antigenic target to which protective 
neutralizing Abs in human sera are directed (82), offers fresh 
avenues for RSV vaccine development with much to be learned 
regarding the potential of this antigen when administered in 
early life.
Systems Biology
Systems biology approaches have been applied to adults and 
older infants but thus far not to newborns (86). This deficiency 
is to soon change with the award of a NIH Human Immunology 
Project Consortium grant to employ systems vaccinology 
to study HBV-induced molecular signatures in relation to 
CoP—i.e., anti-HBsAg Ab responses. Led by the Expanded 
Program on Immunization Consortium, an affiliation of Boston 
Children’s Hospital, Medical Research Council (UK)-Gambia, 
and the University of British Columbia, focused on application 
of systems biology to early life vaccinology, this study will lever-
age transcriptomics and proteomics to provide fresh insights into 
HBV-induced protection in newborns. Among the novel systems 
biology approaches is “systems serology” that offers potential for 
much more precise understanding on the impact of vaccines at 
different ages measuring all aspects of the response, Ab avidity, 
titer, specific, and non-specific responses (87). This approach 
promises to provide deeper insight into the vaccine-induced 
humoral immune responses of distinct populations such as 
human newborns.
In Vitro Modeling to Accelerate and  
De-Risk early Life vaccine Development
Vaccine development is inherently costly, slow, and unfortunately 
beset by multiple failures. Current paradigms of vaccine develop-
ment tend to presume that all populations will respond similarly 
to a given formulation and do not take species-specificity, genetic 
background, and age-specificity into account. Accordingly, many 
vaccine formulations fail or are less effective in vulnerable sub-
populations such as the very young or elderly. In this context, 
human in  vitro platforms that model age-specific vaccine-
induced innate and adaptive immune responses as benchmarked 
to licensed vaccines offer the possibility of accelerating and de-
risking vaccine development (9, 88). Indeed age-specific human 
in vitro platforms such as newborn whole blood assays, dendritic 
cell arrays, and microphysiologic tissue constructs (89) have been 
successfully used to define novel biomarkers of vaccine adjuvan-
ticity (90) and identify TLR7/8 agonists as adjuvants active in 
early life (63).
Overall these technical advances offer powerful new oppor-
tunities to inform, de-risk, and accelerate novel vaccine develop-
ment for use in early life.
iNTeGRATiON iNTO CURReNT 
PROGRAM: CHALLeNGeS AND 
STRATeGieS
Neonatal immunization carries tremendous potential but fur-
ther expansion or enhancement of this approach will require 
both deeper mechanistic insight into how vaccines protect in 
early life as well as integration into the existing framework of 
public health, including maternal immunization programs. 
In response to the concerns of multiple professionals in the 
field of maternal immunization, the Brighton Collaboration 
was formed in 2000, followed by the formation of the Global 
Alignment of Immunization safety Assessment in pregnancy 
(GAIA) to establish safety and efficacy standards in this area 
(91). A collection of case definitions and guidelines for data 
collection, analysis, and presentation of safety data in vaccine 
trials, relevant for neonates and infants, were published by 
global experts, largely in the context of maternal immunization, 
but these are also relevant and of value for monitoring safety 
of neonatal immunization studies (92). Whilst these defini-
tions and guidelines can be amended for the use in neonatal 
immunization studies, the formation of an independent group 
is warranted to establish the framework for safe and efficacious 
neonatal immunization studies.
In 2010, to identify key topics and research gaps in the field and 
foster collaboration among investigators focusing on vaccinol-
ogy and immune ontogeny, a workshop was organized by NIH 
(NIAID; Division of Allergy, Immunology, and Transplantation) 
and cosponsored by the Bill and Melinda Gates Foundation 
(93). Given recent technical and conceptual advances, and their 
potential to vastly transform the area of early life immuniza-
tion, further workshops on optimizing early life immunization, 
including those individuals involved in regulation and safety 
assessments are warranted. The study populations for any ongo-
ing vaccine trials should include not just healthy term infants, 
but a number of distinct populations, including preterm infants 
and those with immunodeficiencies, in particular HIV-exposed 
infected and uninfected [but not unaffected (94)], to ensure pro-
tection of all infants, especially the most vulnerable. Thoughtful 
design of studies, both of maternal and neonatal vaccines, will 
be essential to understand mechanisms underlying vaccine–
vaccine interactions, including interference. It is essential that 
whilst adopting the most advanced systems-based approaches, 
the data are standardized to allow comparison of sample sets 
from the same or different sites. Ongoing reassessment of infant 
immunization schedules will allow the development of more 
effective neonatal vaccine schedules.
CONCLUSiON
Overall, neonatal immunization is a common practice across 
the globe, yet much can be done to optimize its beneficial 
impact. Taking advantage of pivotal opportunities to enhance 
this approach will require engagement with stakeholders, 
including government, funding agencies, and the general pub-
lic, on: (a) the need for greater precision in our understanding 
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of how current neonatal vaccines protect, the potential impact 
of the exact timing of administration in the neonatal period 
(i.e., first 28 days of life) and of vaccine–vaccine interactions, 
(b) assessing how maternal and neonatal immunization can 
be best integrated, and (c) leveraging modern tools including 
systems biology and human in  vitro modeling to study the 
impact of immune ontogeny on vaccine responses thereby 
informing development of novel vaccines for use in early 
life against pathogens for which currently vaccines are inad-
equate (e.g., pertussis, TB, and influenza) or do not yet exist 
(e.g., RSV, HIV).
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